Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)
Clinical trial NCT05465343 · COMPLETED
Trial details
- NCT number
- NCT05465343
- Sponsor
- Peking Union Medical College
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-11
- Primary completion
- 2025-12-12
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.